Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: Main physico-chemical descriptors of the investigated drugs molecular properties.

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques:

Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: Predicted biological activity of the rosiglitazone using the 2023 Molinspiration Cheminformatics bioactivity score v2022.08.

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques: Activity Assay

Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: Rosiglitazone observations gene activities from ChEMBL library based on ChEMBL 20 in eukaryotes and SEA Search server predictions for targets.

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques: Membrane

Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: 3A. Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction. Accessed Jan. 29th, 2023.

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques:

Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: HCC cell lines either Hep3B or HepG2 photographs examined microscopically using an inverted microscope for signs of morphological changes into adipocytes. Cells were stained with Oil Red O working solution. Magnification power x400. Control (Mock) group; HCC cell lines either HepG2 or Hep3B treated with free media, Group 2A: HCC cell lines, either HepG2 or Hep3B treated with 6 µM Sorafenib, 2 µM Rosiglitazone, and 0.5 µM IBMX, 0.86 µM Insulin and 1 µM Dexamethasone, Group 2B: HCC cell lines either HepG2 or Hep3B treated with 6 µM Sorafenib, 4 µM Rosiglitazone, and 0.5 µM IBMX, 0.86 µM Insulin and 1 µM Dexamethasone, Group 3A: HCC cell lines either HepG2 or Hep3B treated with 2 µM Rosiglitazone, and 0.5 µM IBMX, 0.86 µM Insulin and 1 µM Dexamethasone, and Group 3B: HCC cell lines either HepG2 or Hep3B treated with 4 µM Rosiglitazone, and 0.5 µM IBMX, 0.86 µM Insulin and 1 µM Dexamethasone. Magnification power is 400x. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques: Inverted Microscopy, Staining, Control

Journal: Journal of Genetic Engineering & Biotechnology

Article Title: In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

doi: 10.1016/j.jgeb.2024.100429

Figure Lengend Snippet: Alteration of adipogenesis markers in HepG2-treated cells appearing as ADIPOR1 and E-cadherin. The control mock group 1 (Con), Rosiglitazone group (R1): cells treated with rosiglitazone conc. 41 μM, Group 4B: HCC cell line treated with 6 µM Sorafenib, 4 µM Rosiglitazone, 0.5 µM IBMX, 0.86 µM Insulin, and 1 µM Dexamethasone, Sorafenib group (Sora1): cells treated with sorafenib IC 50 conc. 6 μM to evaluate the impact of sorafenib's IC 50 value on its own, Group 5B: HCC cell line treated with 4 µM Rosiglitazone, and 0.5 µM IBMX, 0.86 µM Insulin and 1 µM Dexamethasone. [KDa: kilo Dalton.] Lysates were immunoblotted with an anti-ADIPOR1 antibody and anti-E-cadherin antibody. Representative immunoblot of ADIPOR1 protein, Adipo-R1 (49 kDa) and E-cad (125 kDa). Actin served as loading control.

Article Snippet: Percentage distribution of the macromolecule targets of the small drug Rosiglitazone obtained via the Swiss institute of Bioinformatics (SIB) 2022 powered by ChemAxon SwissTargetPrediction.

Techniques: Control, Western Blot